Investigator-Initiated Trial Tests Immunotherapy Drug for Acute Myeloid Leukemia
In This Video
Watch Ashkan Emadi, MD, PhD, discuss a promising checkpoint inhibitor called indoximod that could leave patients with dramatically lower levels of residual disease than standard chemotherapy alone in the treatment of acute myeloid leukemia (AML).
Dr. Emadi, associate professor at the University of Maryland School of Medicine and a hematologist/oncologist with the Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), is the PI for an investigator-initiated phase I/II clinical trial (NCT02835729) for patients who have been newly diagnosed with AML.
By taking down the indoleamine-(2,3)-dioxygenase (ID0) defense that cancer cells use to evade the immune system, indoximod is demonstrating in solid tumor trials that it can increase the efficacy of chemotherapy, radiation and other checkpoint inhibitors. This is the first time the drug is being used to treat leukemia.
“We used to think of cancer as a genetic disease,” says Dr. Emadi, “but cancer happens as a disease of the host, because our immune system doesn’t recognize the cancer cell as a foreigner.”
- Learn more about indoximod. See an illustration of tumor cells using the IDO pathway to evade the immune system and indoximod countering this phenomenon.
- View Dr. Emadi’s publications on PubMed.
- Schedule Grand Rounds for your hospital with Dr. Emadi.
- Connect with Dr. Emadi on Doximity.
- Learn about current clinical trials at UMGCCC.